Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rated “Hold” by Wall Street Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.18.

A number of research firms recently weighed in on RXRX. Wall Street Zen upgraded Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a research note on Friday, October 16th.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded up $0.02 during trading hours on Friday, reaching $3.52. The company had a trading volume of 15,546,436 shares, compared to its average volume of 29,299,366. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 12-month low of $2.77 and a 12-month high of $5.24. The firm has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $3.52. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -3.91 and a beta of 1.15.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 46.47%. The firm had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. During the same quarter in the previous year, the firm earned ($0.36) earnings per share. Research analysts expect that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 22,408 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. This trade represents a 13.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 167,408 shares of company stock worth $701,276. 6.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of RXRX. Ascent Wealth Partners LLC grew its holdings in Recursion Pharmaceuticals by 11.8% during the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after buying an additional 2,974 shares during the last quarter. Cherry Creek Investment Advisors Inc. increased its position in Recursion Pharmaceuticals by 5.8% during the first quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock worth $217,000 after buying an additional 3,859 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 33.2% in the first quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock worth $52,000 after acquiring an additional 4,199 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock valued at $47,000 after acquiring an additional 5,156 shares during the last quarter. Finally, Axxcess Wealth Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 16.6% during the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock valued at $115,000 after acquiring an additional 5,338 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.